Differential Regulations of Lipid Profiles between Japanese Responders and Nonresponders Treated with Pioglitazone

References

• . Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol. 2009;23(6):675–679
   PubMed Web of Science ®Google Scholar
• . Bloomgarden ZT. Thiazolidinediones. Diabetes Care. 2005;28(2): 488–493
   Google Scholar
• . Tajiri Y, Takei R, Mimura K, Umeda F. Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes. Diabetes Technol Ther. 2007;9(5):429–437
   PubMed Web of Science ®Google Scholar
• . Igarashi M, Jimbu Y, Kimura M, Hirata A, Yamaguchi H, Tominaga M. Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Diabetes Res Clin Pract. 2007;77(3):389–398
   PubMed Web of Science ®Google Scholar
• . Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002;51(8):2341–2347
   PubMedGoogle Scholar
• . Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6(2):133–156
   PubMed Web of Science ®Google Scholar
• . Dormandy JA, Charbonnel B, Eckland DJ, ; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289
   PubMed Web of Science ®Google Scholar
• . Parhofer KG, Otto C, Geiss HC, Laubach E, Göke B. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2–results of a pilot study. Exp Clin Endocrinol Diabetes. 2005;113(1):49–52
   Google Scholar
• . Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract. 2001;7(3):162–169
   Google Scholar
• . Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003;25( suppl B):B64–B80
   Google Scholar
• . Nakayama T, Komiyama N, Yokoyama M, . Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010;138(2):157–165
   Google Scholar
• . Nissen SE, Nicholls SJ, Wolski K, ; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573
   PubMed Web of Science ®Google Scholar
• . Ballantyne CM, Raichlen JS, Nicholls SJ, ; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458–2466
   PubMed Web of Science ®Google Scholar
• . Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol. 2002;89(5A):50C–57C
   PubMed Web of Science ®Google Scholar
• . Brunzell JD, Davidson M, Furberg CD, ; American Diabetes Association; American College of Cardiology. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811–822
   PubMed Web of Science ®Google Scholar
• . Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363–1368
   PubMed Web of Science ®Google Scholar
• . Tominaga M. Diagnostic criteria for diabetes mellitus. Rinsho Byori. 1999;47(10):901–908
   PubMedGoogle Scholar
• . Wang G, Wang X, Zhang Q, Ma Z. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract. 2007;61(4):552–557
   PubMed Web of Science ®Google Scholar
• . Feinböck C, Luger A, Klingler A, ; Austrian Glimepiride Study Group. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab. 2003;16(4):214–221
   PubMedGoogle Scholar
• . Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract. 2000;6(4):305–310
   PubMedGoogle Scholar
• . Kurabayashi M, Yamazaki T; SUBARU Study Group. Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study—more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb. 2008;15(6):314–323
   Google Scholar
• . Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9): 2137–2139
   PubMed Web of Science ®Google Scholar
• . Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab. 2007;9(5):640–647
   Google Scholar
• . Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097–2104
   PubMedGoogle Scholar
• . Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet. 1998;352(9131): 832–833
   Google Scholar
• . Berkenstam A, Gustafsson JA. Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr Opin Pharmacol. 2005;5(2):171–176
   Google Scholar
• . Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10(4):355–361
   PubMed Web of Science ®Google Scholar
• . Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11(5):817–828
   PubMed Web of Science ®Google Scholar
• . Karalis IK, Bergheanu SC, Wolterbeek R, . Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin. 2010;26(10):2301–2313
   PubMed Web of Science ®Google Scholar